[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adenomyosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adenomyosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,44,76,101,140,167,192,217,247,271,297,330,353,374,399,423,445,468,490,515,535],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100534480","artificial-cycle-with-or-without-gnrh-agonist-pre-treatment-for-frozen-embryo-transfer-in-adenomyosis-patients-100534480",false,"NCT06239376","Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients","The Effectiveness of the Two Different Endometrial Preparation Regimes for Frozen Embryo Transfer in Patients With Adenomyosis","FET-ADE","Inclusion Criteria:\n\n* Confirm diagnosis with adenomyosis by using transvaginal ultrasonography (MUSA consensus) and\u002For pelvic magnetic resonance imaging.\n* Age between 18 - 42\n* Undergo less or equal to three previous IVF cycles\n* Indicate for frozen embryo transfer\n* Agree to have not more than two day-3 embryo or one blastocyst (day-5 and day-6) transferred\n* Not participating in any other study\n\nExclusion Criteria:\n\n* Embryos from IVM cycle\n* Having uterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate\u002F bicornuate\u002F arcuate uterus; unremoved hydrosalpinx, endometrial polyp, submucosal leiomyoma, or leiomyoma with endometrial cavity distortion)\n* Having contraindications for exogenous hormones administration: breast cancer, risks of venous thromboembolism\n* Embryos from the oocyte donation cycle.\n* Patients with a history of GnRH injection within three months, measured from the last GnRHa injection to the study screening date.","FEMALE","18 Years","42 Years",{"count":21,"type":22},222,"ESTIMATED","INTERVENTIONAL",[25],"NA","This randomized clinical trial aims to assess the comparative effectiveness of two distinct endometrial preparation protocols for frozen embryo transfer (FET) among women with adenomyosis undergoing IVF\u002FICSI. Specifically, it seeks to address the following key questions:\n\n1. Does the protocol involving the combination of GnRH agonist and letrozole for down regulation with exogenous steroids (GnRHa+AI - AC) result in a higher live birth rate compared to the use of exogenous steroids alone (AC) in women with adenomyosis undergoing frozen embryo transfer?\n2. What are the common side effects of the GnRHa+AI - AC regimen?\n\nEligible participants will undergo screening before endometrial preparation for FET, following which they will be randomly assigned to one of two groups: GnRHa+AI - AC or AC. In the GnRHa+AI - AC group, participants will be pre-treated with GnRH agonist and letrozole two months before endometrial preparation. After this period, participants will return for endometrial preparation, and any side effects resulting from the down regulation will be evaluated. In contrast, the AC group will receive standard treatment.",[28,29,30],"Adenomyosis","IVF","Frozen Embryo Transfer","RECRUITING","2026-06-27",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2024-02-19",{"date":39,"type":22},"2027-05-30",{"name":41,"class":42},"Mỹ Đức Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100608750","the-good-pain-consultation-in-endometriosis-100608750","NCT07205614","The Good Pain Consultation in Endometriosis.","Inclusion Criteria:\n\n* biological women\n\nExclusion Criteria:\n\n* not speaking norwegian","16 Years","50 Years",{"count":53,"type":22},110,[25],"This PhD project investigates the effect of \"the good pain consultation\" and early integration of biopsychosocial pain education with current standard management of endometriosis. Our goal is to facilitate self-management of pain and improve health-related quality of life (HRQOL) using limited resources.\n\nOur research question is: Does a good pain consultation improve pain self-efficacy and HRQOL, compared to usual care at 3 months and 1 year.?\n\nResearchers will compare a good pain consultation to a control group that will receive usual care.\n\nParticipants will:\n\nAttend a consultation and biopsychososial pain education plus usual care or usual care alone.\n\nThey will answer questions in an internet-based questionnaires three times point during the study.",[57,58,59,28,60,61],"Pelvic Pain Syndrome","Endometriosis","Dysmenorrhea","Period Pain","Menstrual Pain",[63,64,65],"pain education","biopsychosocial","randomised controlled trial","2026-04-22",{"date":68,"type":35},"2026-04-28",{"date":70,"type":35},"2025-11-01",{"date":72,"type":22},"2028-06-01",{"name":74,"class":75},"Sorlandet Hospital HF","OTHER_GOV",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":43},"100582529","determination-of-lipocalin-type-prostaglandin-l-pgds-in-blood-urine-vaginal-samples-and-endometrial-ablation-by-enzyme-linked-immunosorbent-assay-100582529","NCT06864494","Determination of Lipocalin Type-prostaglandin (L-PGDS) in Blood, Urine, Vaginal Samples and Endometrial Ablation by Enzyme-linked Immunosorbent Assay","L-PGDS (Lipocalin Type- Prostaglandin) Quantification in Genital, Blood and Urine Samples From Adenomyosis Patients Compared to 2 Control Groups.","ADENO-L","Inclusion Criteria:\n\nCommon inclusion criteria:\n\n* The patient must have given their free and informed consent and signed the consent form\n* The patient must be a member or beneficiary of a health insurance plan\n\nAdenomyosis + group:\n\n* Female.\n* Aged 28 (≥) to 57 (≤) years.\n* Non-menopausal.\n* Having an indication for a total inter-ovarian hysterectomy (excluding oncology).\n* Suffering from adenomyosis.\n\nAdenomyosis - group:\n\n* Female.\n* Aged 28 (≥) to 57 (≤) years.\n* Non-menopausal.\n* Having an indication for a total inter-ovarian hysterectomy (excluding oncology).\n* Suffering from a functional pathology other than adenomyosis.\n\nControl Group:\n\n* Female.\n* Aged 18 (≥) to 57 (≤) years.\n* Asymptomatic: absence of menometrorrhagia and pelvic pain.\n* Support at the medically assisted procreation (MAP) center of the Nîmes University Hospital for male or idiopathic infertility.\n* Indication to perform an endovaginal ultrasound as part of MAP management.\n* Absence of uterine pathology visualized on endovaginal ultrasound.\n\nExclusion Criteria:\n\n* History of autoinflammatory or autoimmune disease.\n* History of atopic or asthmatic conditions.\n* History of sleep apnea syndrome.\n* Chronic or acute renal failure.\n* Liver failure\n* History of active neoplasia or cancer.\n* Taking nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or aspirin in the 15 days prior to L-PGDS concentration measurement\n* Undergoing estrogen-progestin hormonal contraception.\n\nAdenomyosis groups:\n\n\\- Contraindication to MRI.\n\nControl Group:\n\n* Endovaginal ultrasound refused by the patient.\n* Presence of a functional-looking ovarian cyst on imaging (endovaginal ultrasound and\u002For pelvic MRI).","57 Years",{"count":86,"type":22},60,"OBSERVATIONAL","Prostaglandin D2 (PGD2) has anti-inflammatory activity, particularly via Lipocalin type-prostaglandin (L-PGDS). L-PGDS has been studied in pathologies such as sleep apnea, rheumatoid arthritis, asthma and allergic phenomena, but never in adenomyosis. Adenomyosis is a estrogen-dependent multifactorial pathology whose pathophysiology is still poorly defined. This hyperestrogenism causes chronic inflammation, particularly via the activation of the prostaglandin H2 (PGH2) signaling pathway. This would lead to the excess production of prostaglandins E2 (PGE2) and F2a (PGF2a) and the decrease of PGD2 and therefore of L-PGDS, leading to the proliferation of endometrial cells in the myometrium by the epithelial-mesenchymal transition via aromatase. A preliminary study comparing the expression of L-PGDS found a significant decrease in L-PGDS in the uterus of women with adenomyosis lesions versus healthy controls. However, during this study, some information was not collected, including the patients' symptoms, preoperative radiological data and surgical indication. The study authors hypothesize that L-PGDS could be a potential tissue and circulating diagnostic marker of adenomyosis in its early stages. L-PGDS appears to be a good candidate to aid in the diagnosis of adenomyosis via a minimally invasive assay for patients (blood or urine).",[28,58],[91],"lipocalin-Type Prostaglandin D2 Synthase","2026-03-17",{"date":94,"type":35},"2026-03-18",{"date":96,"type":35},"2025-06-25",{"date":98,"type":22},"2027-06",{"name":100,"class":42},"Centre Hospitalier Universitaire de Nīmes",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":120,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":43},"100613355","study-of-endometrial-immune-and-microbiological-modifications-in-cases-of-recurrent-implantation-failure-andor-recurrent-pregnancy-loss-100613355","NCT07265505","Study of Endometrial Immune and Microbiological Modifications in Cases of Recurrent Implantation Failure and\u002For Recurrent Pregnancy Loss","Study of Immune and Microbiological Modifications of the Endometrium in Cases of Recurrent Implantation Failure and\u002For Recurrent Pregnancy Loss","IMERR","Inclusion Criteria:\n\n* Female aged ≥18 and \\\u003C36 years\n* Undergoing assisted reproductive technology (ART) in a fertility center\n* Covered by the French national health insurance system\n* Belonging to one of two groups:\n\n  * Study group: history of recurrent implantation failure (RIF) and\u002For recurrent pregnancy loss (RPL)\n  * Control group: no history of RIF or RPL\n\nExclusion Criteria:\n\n* Pregnant at inclusion\n* Refusal to provide written informed consent\n* Antibiotic use within one month prior to endometrial biopsy Positive serology for hepatitis B, hepatitis C or HIV\n* Uterine anatomical abnormalities (e.g., polyps, cavity-distorting fibroids, untreated hydrosalpinx)\n* Known chromosomal abnormality in either partner\n* Known autoimmune disease, thrombophilia, or antiphospholipid antibody syndrome\n* Persons under legal protection (e.g., guardianship, curatorship)","35 Years",{"count":111,"type":22},100,[25],"The IMERR study aims to improve understanding of certain causes of infertility related to recurrent implantation failure (RIF) and\u002For recurrent pregnancy loss (RPL), conditions that affect many women undergoing assisted reproductive technology (ART). Despite medical advances, some patients repeatedly fail to achieve pregnancy, or experience repeated miscarriages. These situations may be linked to subtle immune or microbial disturbances in the uterus. This study seeks to identify immune and microbiological profiles in the endometrium during the implantation window-a crucial period when the embryo attaches to the uterine wall. We will compare women who have experienced RIF and\u002For RPL with women who have had no such history. Blood and uterine samples will be analyzed to investigate whether certain immune or microbial features are associated with these reproductive failures. The ultimate goal is to uncover predictive factors that may explain why some women experience implantation failure or pregnancy loss, and to lay the foundation for future personalized treatments to improve reproductive outcomes.",[115,116,117,118,119,58,28],"Recurrent Implantation Failure","Recurrent Pregnancy Loss","Infertility, Female","Endometrial Diseases","Endometritis",[121,122,123,124,125,126,127,128,129,28,58],"Uterine Immune Profile","Endometrial Receptivity","Infertility","Recurrent Miscarriage","IVF Failure","Implantation Window","Reproductive Immunology","Endometrial Microbiome","Chronic Endometritis","NOT_YET_RECRUITING","2026-02-03",{"date":133,"type":35},"2026-02-05",{"date":135,"type":22},"2026-04",{"date":137,"type":22},"2031-04",{"name":139,"class":42},"Assistance Publique - Hôpitaux de Paris",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":148,"maxAge":19,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":43},"100586261","fet-in-adenomyosis-100586261","NCT06913075","FET in Adenomyosis","Is GnRH Agonist Plus Letrozole a Better Choice Than GnRH Agonist Alone in Adenomyosis Cases Undergoing Frozen Embryo Transfer?","ADY","Inclusion Criteria:\n\nDiagnosis of adenomyosis confirmed via transvaginal ultrasound as per MUSA criteria History of infertility requiring frozen embryo transfer (FET). Availability of at least one good-quality frozen embryo for transfer\n\nExclusion Criteria:\n\nBMI ≥ 30 kg\u002Fm2 Presence of endocrine disorders; (uncontrolled diabetes mellitus, \u002F hyperprolactinemia, thyroid dysfunction, Congenital adrenal hyperplasia, Cushing syndrome, or polycystic ovary syndrome Previous major uterine surgery Gestational carrier Fertility preservation","21 Years",{"count":150,"type":22},700,[25],"Purpose of the Study:\n\nTo compare the effectiveness of GnRH agonist downregulation alone versus GnRH agonist combined with letrozole in improving pregnancy outcomes in women with adenomyosis undergoing frozen embryo transfer (FET).\n\nResearch Question:\n\nIs the combined use of GnRH agonist and letrozole more effective than GnRH agonist downregulation alone in achieving better ongoing pregnancy rates in adenomyosis cases undergoing FET?\n\nHypothesis:\n\nNull Hypothesis (H₀): The combined use of GnRH agonist and letrozole is not more effective than GnRH agonist downregulation alone in achieving a higher ongoing pregnancy rate in adenomyosis cases undergoing FET.\n\nStudy Outcomes:\n\nPrimary Outcome: Ongoing pregnancy rate at 12 weeks of gestation.",[28],[155,28,156,157],"Frozen embryo transfer","ongoing pregnancy rate","live birth rate","2026-01-23",{"date":160,"type":35},"2026-01-26",{"date":162,"type":22},"2026-06-25",{"date":164,"type":22},"2026-12-23",{"name":166,"class":42},"Indira IVF Hospital Pvt Ltd",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":43},"100389882","phase-2-benefit-of-gnrh-agonist-before-frozen-embryo-transfer-in-patients-with-endometriosis-andor-adenomyosis-100389882","NCT04356664","Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and\u002For Adenomyosis","Benefit of Gonadotropin-releasing Hormone (GnRH) Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and \u002F or Adenomyosis: Randomized Prospective Study","DECATEC","Inclusion Criteria:\n\n* Women aged 18 to 36 years (women ≥18 years to \\\u003C36 years) with endometriosis and \u002F or adenomyosis\n* Having benefited from In vitro fertilisation \u002Fintracytoplasmic micro-injection with freeze all and for whom the frozen embryon transfer of a blastocyst is planned\n* A normal uterine cavity\n* An MRI showing endometriosis and \u002F or adenomyosis during the inclusion visit\n* Having signed a consent form\n* Being affiliated to a Health Insurance Plan.\n\nExclusion Criteria:\n\n* Patient aged \\\u003C18 years and ≥ 36 years\n* BMI\\> 35\n* History of implantation failures (≥ 2)\n* Endometrial alterations: synechiae, polyps, myomas, hyperplasia, hematometra\n* known hydrosalpinx uni or bilateral\n* MRI showing no endometriosis or adenomyosis\n* Hypersensitivity to GnRH, GnRH analogues, or any of the excipients of Decapeptyl 3 mg\n* Known hypersensitivity to estradiol\n* Known hypersensitivity to progesterone\n* Known hypersensitivity to acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs\n* Known hypersensitivity to folic acid\n* Known hypersensitivity to cefixime or an antibiotic in the cephalosporin group\n* Known hypersensitivity to levofloxacin or any other quinolone\n* History of tendinopathies related to the administration of fluoroquinolones\n* Epilepsy\n* Hypersensitivity to contrast agents for MRI\n* Known or suspected breast cancer or history of breast cancer\n* Known or suspected genital tract cancer or history of genital cancer\n* known or suspected estrogen-dependent malignant neoplasms\n* Undiagnosed genital haemorrhage\n* Untreated endometrial hyperplasia\n* History of idiopathic venous thrombo-embolic accident or evolving venous thrombo-embolic event (deep vein thrombosis, pulmonary embolism)\n* Recent or evolving arterial thromboembolic stroke (eg angina, myocardial infarction)\n* Acute liver disease or history of liver disease, until hepatic tests are normalized\n* Severe renal insufficiency\n* Severe, uncontrolled heart failure\n* Evolutionary gastroduodenal ulcer\n* History of asthma caused by the administration of salicylates or substances of similar activity, especially nonsteroidal anti-inflammatory drugs\n* GnRH Agonist Decapeptyl administered within 6 months prior to transfer\n* To be deprived of liberty or under guardianship\n* Pregnancy and breast feeding.","36 Years",{"count":177,"type":22},180,[179,180],"PHASE2","PHASE3","Women suffering from endometriosis and\u002For adenomyosis may also suffer from infertility. GnRH agonist injection could improve implantation and therefore increase the pregnancy rate in these patients. This study was designed to evaluate effects of the additional of GnRH agonist (single or 2 doses) to the routine oestrogens and progestins use as support before Frozen Embryon Transfer as compared to oestrogens and progestins only.",[58,28,117],"2026-01-15",{"date":185,"type":35},"2026-01-16",{"date":187,"type":35},"2021-03-18",{"date":189,"type":22},"2026-06-18",{"name":191,"class":42},"Hopital Foch",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":200,"targetDuration":202,"studyType":87,"phases":4,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":43},"100399448","clinical-and-molecular-study-of-endometriosis-and-adenomyosis-100399448","NCT04481321","Clinical and Molecular Study of Endometriosis and Adenomyosis","ENDOCHAP Monocentric Cohort: Clinical and Molecular Study of Endometriosis and Adenomyosis","ENDOCHAP","Inclusion Criteria:\n\n* Women of age between - 18 and 42 years old.\n* In-service care for one of the pelvic pain and\u002For infertility, or for a pelvic mass.\n* Having a radiological diagnosis made by a referral practitioner and\u002For operated in the department\n\nExclusion Criteria:\n\n* HIV-positive women, HBV and HCV\n* During pregnancy\n* Having a cancer diagnosis\n* Refusing to sign a consent.",{"count":201,"type":22},5300,"10 Years","The purpose of this study is to determine whether endometriosis and adenomyosis are progressive diseases, in terms of symptoms (pain, abnormal uterine bleeding and infertility), anatomical lesions size, and recurrences. We also aimed to address molecular questions on immune dialogues between ectopic lesions and the eutopic endometrium, auto-immunity in endometriosis and adenomyosis and the role of the microbiota in their respective pathophysiologies.",[58,28],[58,28,206,207,208],"pain","infertility","disease progressiveness","2025-11-17",{"date":211,"type":35},"2025-11-20",{"date":213,"type":35},"2006-05",{"date":215,"type":22},"2040-12",{"name":139,"class":42},{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":224,"sex":17,"minAge":18,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":246},"100560108","next-generation-endometriosis-diagnostics-through-comprehensive-multi-dimensional-analysis-100560108","NCT06572852","Next-Generation Endometriosis Diagnostics Through Comprehensive Multi-Dimensional Analysis","AdEnd","Inclusion Criteria:\n\nParticipants eligible for cases with endometriosis and adenomyosis, must meet the following criteria:\n\n* Able to give informed consent for participation in the study.\n* European descent.\n* Confirmed diagnosis of both endometriosis and adenomyosis through ultrasound screening.\n* Listed for assisted reproductive treatment, specifically within their first or second IVF cycle.\n\nParticipants eligible for cases with only endometriosis must meet the following criteria:\n\n* Able to give informed consent for participation in the study.\n* European descent.\n* Confirmed diagnosis of endometriosis with no ultrasound evidence of adenomyosis.\n* Enrolled in an assisted reproductive treatment cycle involving embryo thawing.\n\nParticipants eligible for cases with only adenomyosis must meet the following criteria:\n\n* Able to give informed consent for participation in the study.\n* European descent.\n* Confirmed diagnosis of adenomyosis with no ultrasound evidence of endometriosis.\n* Enrolled in an assisted reproductive treatment cycle involving embryo thawing.\n\nParticipants eligible as controls must meet the following criteria:\n\n* Able to give informed consent for participation in the study.\n* European descent.\n* Undergone ultrasound screenings that have excluded the presence of endometriosis or adenomyosis.\n* Listed for assisted reproductive treatment, specifically within their first or second IVF cycle.\n* Presence of reduced ovarian reserve or non-severe male factor infertility.\n\nExclusion Criteria:\n\n* Patients unable or unwilling to sign the informed consent\n* Individuals who exhibit the presence of sactosalpinx or other uterine pathologies such as fibroids, polyps, or irregular endometrial thickening will be excluded from participation in this study.\n\nThese exclusion criteria are applicable across all groups to ensure the accuracy and reliability of the study's findings related to endometriosis and adenomyosis.",true,"40 Years",{"count":227,"type":22},530,"This study is a multicentric, observational, case-control, non-profit with additional procedures. It aims to deepen the understanding of the chronic gynecological conditions of endometriosis and adenomyosis, which significantly impact women's reproductive health. Its purpose is to improve early diagnosis and personalized treatment of these conditions using a multi-omic approach, that integrates genetic, epigenetic, imaging, and endometrial receptivity data. The goal is also to refine image-based predictions through recent advancements in artificial intelligence and to study uterine extracellular vesicles to assess fertility non-invasively.\n\nThe study targets patients with endometriosis and\u002For adenomyosis and involves women seeking fertility treatments at assisted reproduction centers, who will serve as a control population.\n\nThe study comprises both prospective and retrospective components. The prospective recruitment involves the collection of blood and uterine fluid samples, while the retrospective element utilizes pre-existing biobank samples for comprehensive genetic and epigenetic analysis.",[58,28],[231,232,233,234,58,28,235,236],"Case-control","Retrospective","Prospective","Genetic","Machine learning","Epigenetic","2025-10-02",{"date":239,"type":35},"2025-10-07",{"date":241,"type":35},"2024-11-07",{"date":243,"type":22},"2026-08-30",{"name":245,"class":42},"IRCCS San Raffaele",2,{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":23,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":43},"100567082","comparing-the-efficacy-of-tu-less-and-vnotes-for-hysterectomy-of-enlarged-uterus-100567082","NCT06663553","Comparing the Efficacy of TU-LESS and vNOTES for Hysterectomy of Enlarged Uterus","Protocol for a Comparative Study of the Efficacy of Transumbilical Laparoendoscopic Single-site Surgery (TU-LESS) and Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) in Hysterectomy Performed on Patients With Enlarged Uterus: A Prospective Single-blinded, Randomized Clinical Trial","Inclusion Criteria:\n\n* Eligible women aged 18-70 years.\n* Women with indications for enlarged uterine volumes who are planning to under go total hysterectomy. Uterine size should exceed that of a 3-month pregnancy (uterine weight ≥ 280 g).\n* Patients are willing to be randomly assigned to undergo any of both approaches.\n* Patients who are willing to sign the informed consent form.\n\nExclusion Criteria:\n\n* Individuals who are virgins or have vaginal stenosis.\n* Patients requiring concurrent surgical intervention for conditions such as ovarian cysts or lesions of the vulva, vagina, appendix, etc.\n* presence of uterus exceeding approximately 20 gestational weeks in size (about 900-1000g), which is beyond the limitations of a single-site laparoscopic approach due to concerns regarding technical feasibility and safety\n* Presence of malignancy or strong suspicion of malignancy that may alter the planned surgical approach.\n* History of two or more pelvic surgeries or suspected severe pelvic adhesions (rectovaginal examination suggesting rectovaginal endometriosis or limited uterine mobility).\n* History of peritoneal dialysis, pelvic radiation therapy and pelvic tuberculosis treated with laparoscopic surgery.\n* Patients with prolapse or pelvic inflammation.\n* Diabetes mellitus with poor blood glucose control.\n* Body mass index greater than 30 kg\u002Fm².","70 Years",{"count":256,"type":22},210,[25],"Enlarged uterus is frequently encountered in clinical practice, and its incidence due to conditions such as adenomyosis, uterine fibroids, and other gynecological disorders has steadily increased over the years statistically. For example, greater healthcare awareness has led to more frequent early diagnoses of these conditions, contributing to the observed rise in incidence. Additionally, increasing life expectancy results in more women reaching the perimenopausal and postmenopausal stages, during which conditions like uterine fibroids and adenomyosis become more prevalent. For these women, hysterectomy (removal of the entire uterus) is often the recommended option of treatment.\n\nWith advances in surgical techniques over recent decades, there has been a notable shift from traditional open abdominal surgeries to minimally invasive approaches. Laparoscopic surgery has been widely adopted, significantly reducing the size and number of incisions required, thereby promoting faster recovery, minimizing postoperative pain, and reducing the risk of complications.\n\nHowever, conventional multi-port laparoscopic hysterectomy still presents certain challenges, such as large uterus extraction following resection, and concerns about healing of incisions. In contrast, innovative techniques like Transumbilical Laparoendoscopic Single-Site Surgery(TU-LESS) and Transvaginal Natural Orifice Transluminal Endoscopic Surgery(vNOTES) both take advantage of natural anatomical openings to achieve minimal or no visible scarring. Studies demonstrate that these techniques provide superior outcomes in terms of reduced pain, faster recovery, and quicker return to daily activities compared to traditional multi-port laparoscopic approaches.\n\nYet a direct comparison of the efficacy of these two methods in real-world, particularly for enlarged uterus, remains inconclusive. Thus this study aims to evaluate and compare the outcomes of these two techniques in patients with enlarged uteri. Participants will be randomly assigned to receive one of the two surgical approaches, ensuring an unbiased comparison of the efficacy of the procedures in terms of healing status and recovery time.",[260,28,261],"Enlarged Uterus","Uterine Fibroids (UF)","2025-09-16",{"date":264,"type":35},"2025-09-18",{"date":266,"type":22},"2025-10-01",{"date":268,"type":22},"2028-10",{"name":270,"class":42},"West China Second University Hospital",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":23,"phases":282,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":293,"leadSponsor":295,"locationsCount":43},"100577738","a-randomized-study-comparing-subtotal-vs-total-hysterectomy-long-term-outcomes-100577738","NCT06802198","A Randomized Study Comparing Subtotal vs Total Hysterectomy Long Term Outcomes","Comparison of Long-Term Outcomes Following Laparoscopic Total Vs Supracervical Hysterectomy, a Randomized Clinical Trial","STORY","Inclusion Criteria:\n\n* Age\\>18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* Uterine or adnexal pathology suspect for malignancy\n* Abnormal or unknown PAP test\n* Patients with invasive neoplasia in the previous 5 years (excluding non-melanoma skin tumors, breast cancer T1 N0 M0 Grade 1 or 2 without signs of recurrence or activity).\n* Previous radical pelvic surgery or radiotherapy;\n* Age \\> 80 years\n* Pregnant patients\n* Desire for further pregnancies\n* Contraindications to general anaesthesia or to the Trendelenburg position\n* Refusal to sign informed consent","80 Years",{"count":281,"type":22},500,[25],"The goal of this randomized clinical trial is to assess the outcomes of total laparoscopic hysterectomy vs subtotal laparoscopic hysterectomy + mini-laparotomy for uterine extraction for benign gynecological conditions in terms of change in quality of life at 36 months after surgery and patient's impression of improvement. The secondary objectives of the study are to assess any differences in terms of peri and postoperative outcomes (postoperative pain, blood loss, hospital stay, intraoperative or short and long-term postoperative complications, long term urinary, bowel and pelvic floor symptoms, prevalence of vaginal cuff dehiscence).\n\nParticipants will fill the following questionnaires pre-operatively and at the follow up:\n\n* Short Form 36 (SF36),\n* Euro Quality of life 5D-3L (EQ 5D-3L)\n* Female Sexual Function Index (FSFI)\n* Patient Global Impression of Improvement (PGI-I) only during the follow-up period.",[285,286,28,287,58,288],"Fibroid Uterus","Metrorrhagia","Benign Gynecologic Neoplasm","Abnormal Uterine Bleeding","2025-09-04",{"date":291,"type":35},"2025-09-05",{"date":266,"type":22},{"date":294,"type":22},"2030-02-01",{"name":296,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":224,"sex":17,"minAge":305,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":308,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":329},"100541645","pain-in-endometriosis-and-the-relation-to-lifestyle-100541645","NCT06332560","Pain in Endometriosis And the Relation to Lifestyle","Pain in Endometriosis And the Relation to Lifestyle: Effectiveness of a Dietary Intervention and Cognitive Behavioral Therapy in Endometriosis-associated Pain","PEARL","Inclusion Criteria:\n\n* Confirmed diagnosis of endometriosis via ultrasound, MRI or surgery\\*\n* NRS pain score \\> 4\\*\n* Age from 17 years\n* Premenopausal status\n* Body Mass Index (BMI) 18-30 kg\u002Fm2\n* Ability to understand the explanation about the diet intervention (DI) and CBT\\*\n* Willing to follow the DI\\*\n* Willing to continue their use of food supplements\n* Willing to undergo CBT\\*\n* Willing to collect menstrual effluent, and therefore willing to have two stop weeks from hormonal contraception (if applicable) during the study period.\n\nExclusion Criteria:\n\n* Recurrent miscarriages (\\> 2)\n* Eating disorder\n* Diagnosed with Crohn's disease, Ulcerative Colitis, short bowel syndrome or another chronic inflammatory disease\n* Self-reported celiac disease\n* Vegan diet\n* Smoking\n* Use of immunosuppressive or psychotropic medication\n* Score on FFQ \\> 120\n* Diagnosed with severe mental disorder currently requiring treatment by psychiatrist\n* NRS average score below 4 during the last month\n* Participation in another intervention study\n* Unable to speak Dutch or to understand the intervention\n* Need for surgery during the participation in the study\n* Serious pain (NRS \\> 4) from other origin than endometriosis\n* Pregnant\n* Scalp hair shorter than 4 cm\n\n  * Only applicable to patients with endometriosis","17 Years",{"count":307,"type":22},250,[25],"The goal of this clinical trial is to investigate the effect of an anti-inflammatory diet and cognitive behavioral therapy (CBT) on pain symptoms, health related quality of life and the effect on inflammatory characteristics in serum and menstruum samples as well as the effect on the gut and vaginal microbiome in women with endometriosis. In addition, we want to investigate the differences in stress (measured by hair cortisol levels), inflammatory markers in peripheral blood, menstrual effluent, and the vaginal and intestinal microbiome between persons without and with endometriosis. Participants will be randomized between standard care (control group), standard care and an anti-inflammatory diet intervention, or standard care, an anti-inflammatory diet intervention and CBT or CBT alone. Participants will follow an anti-inflammatory diet based on the Dutch Dietary Guidelines or CBT or a combination of both interventions for 12 weeks. They will receive personalized dietary advice from a dietician and recipes will be available. cognitive behavioral therapy will be administered in a total of seven individual sessions led by a psychotherapist. The content of these sessions will be psycho-education regarding pain mechanisms (and diet).",[58,28],[312,206,313,314,315,316,317,318,319],"endometriosis","quality of life","immunology","anti-inflammatory diet","cognitive behavioral therapy","adenomyosis","diet","microbiome","2025-08-05",{"date":322,"type":35},"2025-08-11",{"date":324,"type":35},"2024-10-04",{"date":326,"type":22},"2027-05",{"name":328,"class":42},"Radboud University Medical Center",5,{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":337,"targetDuration":4,"studyType":23,"phases":339,"briefSummary":340,"conditions":341,"keywords":343,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":43},"100544108","electroacupuncture-for-dysmenorrhea-secondary-to-adenomyosis-100544108","NCT06364592","Electroacupuncture for Dysmenorrhea Secondary to Adenomyosis","Effect of Electroacupuncture for Dysmenorrhea Secondary to Adenomyosis: an Exploratory Pilot Study","Inclusion Criteria:\n\n* Meeting the diagnosis criteria of dysmenorrhea secondary to adenomyosis.\n* Female patients aged between 18 and 50.\n* Dysmenorrhea lasting for 3 consecutive menstrual cycles or more.\n* At least three consecutive menstrual cycles with an interval of 24 to 38 days, differing by less than 7 days, and menstrual periods lasting 2 to 8 days before screening.\n* At least 2 days of worst pain score ≥4 on Numerical Rating Scale during the screening period.\n* Having not used medications, other than rescue medicine, or therapies for dysmenorrhea secondary to adenomyosis for at least 1 month before randomization, and consenting not to use throughout the process of the research.\n* Volunteering to participate the trial and signing written informed consent.\n\nExclusion Criteria:\n\n* Diagnosed with Endometriosis or having a history of endometriosis-related surgery\n* Currently taking hormonal medications, including: a.use of GnRH agonists within 6 months before the screening period; b. use of progestins or danazol and other long-acting hormones within 3 months before the screening period; c. use of oral contraceptive-like short-acting hormones within one month before the screening period;\n* Having clinically significant gynecologic condition such as clinically significant endometrial pathology, persistent complex ovarian cyst larger than 3 cm or simple ovarian cyst larger than 5 cm, or single fibroid 4 cm or larger or more than 4 fibroids measuring at least 2 cm or symptomatic submucosal fibroid of any size.\n* having an IUD.\n* HB \\\u003C 90G\u002FL.\n* Having any other chronic pain syndrome that required chronic analgesic or other chronic therapy.\n* Having a current history of undiagnosed abnormal genital bleeding.\n* Malignant tumors (including the reproductive system and other systems).\n* Combined with severe diseases in the cardiac, respiratory, renal, liver, and hematopoietic systems, psychiatric disorder and\u002For cognitive disorders.\n* Pregnant, breast feeding, planning a pregnancy within the next 7 months.",{"count":338,"type":22},30,[25],"The aim of this study is to preliminarily evaluate the is to assess the effects and safety of electroacupuncture for moderate to severe dysmenorrhea secondary to adenomyosis.",[59,28,342],"Electroacupuncture",[59,28,342],"2025-08-01",{"date":346,"type":35},"2025-08-06",{"date":348,"type":35},"2024-07-21",{"date":350,"type":22},"2026-12-31",{"name":352,"class":42},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":362,"conditions":363,"keywords":364,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":43},"100428664","observational-study-of-patients-suffering-from-endometriosis-and-adenomyosis-100428664","NCT04862000","Observational Study of Patients Suffering From Endometriosis and Adenomyosis","Prospective Long Term Observational Study of Health Profile, Clinical Characteristics and Outcome of Patients Suffering From Endometriosis and Adenomyosis","Inclusion Criteria:\n\n* with endometriosis or adenomyosis confirmed by ultrasound or MRI\n\nExclusion Criteria:\n\n* refuse to participate in the study, less than 18 years old, menopausal, illiterate or mentally incapable",{"count":361,"type":22},880,"Endometriosis and adenomyosis are chronic difficult diseases affecting a significant proportion of reproductive age women. it is hoped that the investigators can collect the health profile of these participants using structured questionnaires on their quality of life, reproductive health, collect the sonographic characteristics, identify the risks factors of participants suffering from severe disease, and to propose the best treatment modality for different patient groups, both with and without fertility wish.",[58,28],[58,28],"2025-06-03",{"date":367,"type":35},"2025-06-05",{"date":369,"type":35},"2021-04-30",{"date":371,"type":22},"2032-12-31",{"name":373,"class":42},"Chinese University of Hong Kong",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":224,"sex":17,"minAge":18,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":385,"conditions":386,"keywords":387,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":397,"locationsCount":43},"100592297","fertility-limiting-diseases-of-pelvic-organs-and-their-influence-on-receptivity-of-endometrial-cavity-prospective-clinical-trial-100592297","NCT06991595","Fertility Limiting Diseases of Pelvic Organs and Their Influence on Receptivity of Endometrial Cavity: Prospective Clinical Trial","Fertility Limiting Diseases of Pelvic Organs and Their Influence on Receptivity of Endometrial Cavity: Prospective Clinical Trial (REAdME)","REAdME","Inclusion Criteria:\n\n* agreement with participation in the study\n* age between 18 - 45 years (at the start of patient´s participation in the study)women with at least 1 year infertility\n\nExclusion Criteria:\n\n\\-","45 Years",{"count":384,"type":22},236,"In this project, we will characterize the effects of fertility limiting diseases of pelvic organs on the receptivity of the endometrium. The primary aim of the project is the characterization of endometrium in patients with infertility suffering from AD, UF and DE, and compare it with infertile patients with minimal or mild endometriosis but no AD or UF (ETRS group), and with healthy women with only male factor of infertility (CTRL group, controls). The proper infertility treatment of patients with AD,UF and endometriosis is controversial and lacking clear evidence based algorithms. Despite their topical character, especially AD and DE (and UFs as well if present as multiple lesions) can be classified as systemic diseases in relation to women´s fertility. The presumed impact of these pathologies to endometrial receptivity (no matter they do not occur in the uterine cavity itself) can beseen as a fascinating hypothesis. Eradication of these diseases could have a potential to increase the prognosis of these women fundamentally.",[28,285,58],[317,388,389,312,390],"cytoreductive resection","myomectomy","endometrial receptivity","2025-05-18",{"date":393,"type":35},"2025-05-28",{"date":395,"type":35},"2023-04-01",{"date":350,"type":22},{"name":398,"class":42},"Charles University, Czech Republic",{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":406,"enrollmentInfo":407,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":409,"conditions":410,"keywords":411,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":43},"100577239","validation-and-optimisation-of-ultrasound-diagnosis-of-adenomyosis-100577239","NCT06795711","Validation and Optimisation of Ultrasound Diagnosis of Adenomyosis","Validation and Optimisation of Ultrasound Diagnosis of Adenomyosis: a Prospective Observational Study","Inclusion Criteria:\n\n* age between 18 and 60;\n* obtaining informed consent\n\nExclusion Criteria:\n\n* Hysterectomised patients;\n* Virgo patients (hymenal integrity);\n* Patients reporting intolerance to transvaginal ultrasound;\n* Gynaecological oncology;\n* Recent pregnancy or childbirth (within 6 months);\n* Menopausal patients","60 Years",{"count":408,"type":22},465,"Defining ultrasound criteria for normal uterine biometry and assessing the prevalence of repeat abortions in patients with abnormalities of the uterine cavity",[28],[317,412,413],"gynaecology","ultrasound","2025-01-21",{"date":416,"type":35},"2025-01-28",{"date":418,"type":35},"2022-04-04",{"date":420,"type":22},"2025-03-31",{"name":422,"class":42},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":17,"minAge":430,"maxAge":51,"enrollmentInfo":431,"targetDuration":4,"studyType":23,"phases":432,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":43},"100571413","phase-1-ttt-of-adenomyosis-100571413","NCT06719934","Ttt of Adenomyosis","Dienogest Versus Uterine Artery Embolization in Ttt of Adenomyosis -cohort Comparetive Study","Inclusion Criteria:- Age Group: 30-50 years\n\n* Women with adenomyosis\n* With or without small fibroids\n* Suffering from heavy menstrual bleeding, dysmenorrhea, and\u002For cycle- independent pain and bulk-related symptoms.\n\nExclusion Criteria:\n\n* \\- Presence of a malignancy or pelvic infection.\n* An on-going pregnancy or a desire to conceive in the future.\n* Absolute contraindication for angiography (renal impairment).\n* Chronic debilitating diseases.","30 Years",{"count":111,"type":22},[433],"PHASE1","to evaluate use of Dienogest versus uterine arteries embolization in treatment of Adenomyosis-associated symptoms as dysmenorrhea, heavy menstrual bleeding and bulk-related symptoms",[28],"2024-12-02",{"date":438,"type":35},"2024-12-06",{"date":440,"type":22},"2025-01-01",{"date":442,"type":22},"2026-01-01",{"name":444,"class":42},"Al-Azhar University",{"id":446,"slug":447,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":452,"enrollmentInfo":453,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":455,"conditions":456,"keywords":457,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":43},"100571272","risk-factors-associated-with-the-progression-of-adenomyosis-100571272","NCT06718088","Risk Factors Associated With the Progression of Adenomyosis","Risk Factors Associated With The Progression Of Adenomyosis","Inclusion Criteria:\n\n* Patients aged between 18 and 55 years;\n* Presence of at least two direct and indirect signs according to the MUSA classification\n* Obtaining informed consent\n\nExclusion Criteria:\n\n* Patients undergoing hysterectomy;\n* Virgo patients;\n* Patients reporting intolerance to transvaginal ultrasound;\n* Gynaecological oncology;\n* Recent pregnancy or childbirth (within 6 months)","55 Years",{"count":454,"type":22},258,"Adenomyosis is a gynaecological disorder with a high prevalence in women of childbearing age and is characterised by the presence of endometrial glands and stroma within the myometrium, associated or not with hypertrophy and hyperplasia of the surrounding myometrium. Adenomyosis may cause pelvic pain and\u002For abnormal uterine bleeding.\n\nTransvaginal ultrasound (TVUS) is considered the main non-invasive diagnostic modality for the diagnosis of adenomyosis.\n\nAlthough adenomyosis is a very common condition among patients of childbearing age, its natural course is still debated. Some studies have evaluated the role of hormonal treatments (systemic or local oestrogen or progestin-based) on adenomyosis, which have been effective in controlling symptoms such as pelvic pain and abnormal uterine bleeding. Despite all this, no evidence is available on the progression of adenomyosis and the factors that may influence its progression over time. The aim of this study is therefore to assess the progression of adenomyosis and associated risk factors using transvaginal ultrasound.",[28],[317,458,459],"risk factors","transvaginal ultrasound","2024-12-01",{"date":462,"type":35},"2024-12-05",{"date":464,"type":35},"2022-06-01",{"date":466,"type":22},"2026-06-01",{"name":422,"class":42},{"id":469,"slug":470,"hasResults":11,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":11,"sex":17,"minAge":430,"maxAge":452,"enrollmentInfo":476,"targetDuration":4,"studyType":23,"phases":478,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":43},"100378559","comparing-efficacy-of-microwave-vs-embolization-treatment-for-adenomyosis-100378559","NCT04209127","Comparing Efficacy of Microwave Vs Embolization Treatment for Adenomyosis","Single Blinded Randomized Controlled Study of Symptom Improvement After Uterine Artery Embolization (UAE) Versus Ultrasound Guided Percutaneous\u002Ftransvaginal Microwave Ablation, Evaluated by Validated Questionnaires","ADENOMIC","Inclusion Criteria:\n\n* Healthy women aged 30-55 with symptomatic adenomyosis\n* Premenopausal\n* Adenomyosis diagnosted by TVUS\n* Willing to comply with protocol\n\nExclusion Criteria:\n\n* Body Mass Index \\>35\n* Treatment with anticoagulant\u002Fbleeding disorder\n* Contraindication for UAE or general anesthesia",{"count":477,"type":22},70,[25],"Single blinded randomized controlled study of symptom improvement after uterine artery embolization (UAE) versus ultrasound guided percutaneous\u002Ftransvaginal microwave ablation, evaluated by validated questionnaires.\n\nAdenomyosis is a benign condition causing pain and bleeding disorders in many women. Hysterectomy has historically been the golden standard for treatment as well as (postoperatively) diagnosis of the disease. In accordance with refined diagnostic tools such as ultrasound and\u002For MRI, minimally invasive treatments for adenomyosis are being explored.\n\nWe plan to compare two minimally invasive techniques: embolization of the uterine artery (a commonly used procedure) and microwave ablation of adenomyotic tissue (previously only in clinical use in China).",[28],"2024-11-18",{"date":483,"type":35},"2024-11-20",{"date":485,"type":35},"2020-09-16",{"date":487,"type":22},"2026-06-30",{"name":489,"class":42},"Karolinska Institutet",{"id":491,"slug":492,"hasResults":11,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":452,"enrollmentInfo":497,"targetDuration":4,"studyType":23,"phases":499,"briefSummary":500,"conditions":501,"keywords":503,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":513,"locationsCount":4},"100552892","hysteroscopic-suture-fixation-of-mirena-in-the-treatment-of-adenomyosis-100552892","NCT06478992","Hysteroscopic Suture Fixation of Mirena in the Treatment of Adenomyosis","A Multicenter Randomized Controlled Trial of Hysteroscopic Suture Fixation of Mirena in the Treatment of Adenomyosis","Inclusion Criteria:\n\n* Pain due to adenomyosis (lower abdominal pain and low back pain) visual analogue scale (VAS) ≥40mm or menstrual volume score (PBAC) ≥100;\n\n  * Adenomyosis was confirmed by ultrasound or magnetic resonance imaging (MRI);\n\n    * The uterine volume measured by transvaginal gynecological three-dimensional ultrasound was more than 150cm3 and less than 280cm3 (the volume was about 280cm3 at 10 weeks of pregnancy); ④ A strong desire to preserve the uterus; ⑤ No fertility requirements within nearly one year;\n\n      * Premenopausal women aged ≥18 years old; ⑦ Willing and able to abide by the study protocol, and have the ability to clearly judge the amount of menstruation and the degree of pain.\n\nExclusion Criteria:\n\n* Presence of contraindications to Mirena (known or suspected pregnancy, current pelvic inflammatory disease or recurrent pelvic inflammatory disease, lower genital tract infection, postpartum endometritis, infectious abortion within the past 3 months, cervicitis, cervical dysplasia, uterine or cervical malignant lesions, progestin-dependent tumors, abnormal uterine bleeding of unknown cause, congenital or acquired uterine abnormalities, these include fibroids that deform the cervix, conditions that increase susceptibility to infections, acute liver diseases or tumours, allergy to active ingredients or excipient);\n\n  * Malignant tumors (including reproductive system and other systems);\n\n    * Acute stage of heart, liver and kidney failure or other patients who cannot tolerate operation;\n\n      * The history of Mirena displacement or expulsion;\n\n        * Ultrasound showed the presence of ovarian chocolate cyst; ⑥ The presence of deep endometrial nodules by gynecological examination;\n\n          * The presence of intramural or subserous myoma ≥3cm or any size of uterine submucosal myoma (type 0, 1, 2); ⑧ Patients who are unwilling to participate in the study or who were considered by the investigators to be unsuitable for the study.",{"count":498,"type":22},144,[25],"The purpose of this study was to evaluate the efficacy and safety of hysteroscopic Mirena fixation in patients with adenomyosis with enlarged uterus, compared with simple Mirena placement under hysteroscopy. Whether the curative effect is not inferior to and reduces the incidence of Mirena expulsion.",[28,502],"Hysteroscopy",[504,505,506,28],"Suture fixation","Expulsion","Mirena","2024-06-23",{"date":509,"type":35},"2024-06-27",{"date":511,"type":22},"2024-06-30",{"date":487,"type":22},{"name":514,"class":42},"First People's Hospital of Hangzhou",{"id":516,"slug":517,"hasResults":11,"nctId":518,"briefTitle":519,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":224,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":524,"conditions":525,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":43},"100544817","new-perspectives-in-adenomyosis-pathogenesis-with-epigenetic-analysis-and-mirnas-100544817","NCT06373822","New Perspectives in Adenomyosis Pathogenesis With Epigenetic Analysis and miRNAs","ADENO-MIRNA","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Pre-menopausal\n\nExclusion Criteria:\n\n* HIV or Hepatitis-positive\n* having participated in another clinical study in the 12 months prior to recruitment\n* presenting symptoms of endometriosis",{"count":523,"type":22},50,"Objectives:\n\nTo identify differentially expressed miRNAs in the blood of adenomyosis patients in view to develop new diagnostic methods\n\nHypotheses Circulating miRNAs may be abnormally expressed in patients suffering from adenomyosis and could be used to diagnose the disease\n\nStudy Design Blood samples will be collected from healthy subjects and adenomyosis patients and miRNAs will be isolated and analyzed to detect potential differences.",[28],"2024-04-18",{"date":528,"type":35},"2024-04-22",{"date":530,"type":35},"2024-03-21",{"date":532,"type":22},"2031-09",{"name":534,"class":42},"Université Catholique de Louvain",{"id":536,"slug":537,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":225,"enrollmentInfo":542,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":43},"100525610","adenomyosis-patients-with-infertility-and-immunological-factors-100525610","NCT06123975","Adenomyosis Patients With Infertility and Immunological Factors","Study of the Role of Immunologic Factors in Adenomyosis Patients With Infertility","Inclusion Criteria:\n\n* Patients were diagnosed as adenomyosis by transvaginal ultrasound scans (The criteria for sonographic diagnosis of adenomyosis are with 2 or more of the following: heterogeneous myometrial texture with the presence of globular asymmetric uterus, thickening of the anterior and posterior myometrial wall, irregular cystic areas within the myometrium);\n* 18≤ age ≤ 40 years old at first outpatient visit in our Reproductive Center;\n* with regular menstrual cycle.\n\nExclusion Criteria:\n\n* Patients with intrauterine adhesion, uterine malformation, submucosal leiomyoma, or ≥ 5.0 cm in diameter leiomyoma;\n* hydrosalpinx and systemic diseases;\n* patients with other endocrine severe diseases, immune diseases, tumors and abnormal chromosomes in either partner.",{"count":543,"type":22},200,"Infertile patients with adenomyosis who met the inclusion and exclusion criteria, after signing the informed consent form, the researchers recorded the clinical information of the patients and initiated the in vitro fertilization-embryo transfer (IVF-ET) procedure. Peripheral blood was collected on the day of embryo transfer. And if the pregnancy test was positive at 14 days after embryo transfer, peripheral blood was collected at 21 days after the transfer and every 2 weeks thereafter until 12 weeks of gestation. By analyzing the changes of immune cells and molecules in the peripheral blood of the patients, role of immune factors in infertility combined with adenomyosis was further explored.",[28],"2024-04-11",{"date":548,"type":35},"2024-04-15",{"date":550,"type":35},"2024-03-01",{"date":552,"type":22},"2026-10-01",{"name":554,"class":42},"Peking University Third Hospital"]